From: Purinergic signalling pathway: therapeutic target in ovarian cancer
S. no. | Receptor subtypes | Preferred natural ligand | Role of purinergic receptors in ovarian cancer | References |
---|---|---|---|---|
P1 Adenosine receptors [G protein coupled receptor] | ||||
 1. | A1R | Adenosine | Immune activation and tumour suppression | |
 2. | A2AR | Adenosine | Immune suppression and pro-tumour effects | |
 3. | A2BR | Adenosine | Immune suppression and pro-tumour effects | |
 4. | A3R | Adenosine | Immune activation and tumour suppression | |
P2 Purinergic receptors | ||||
1. P2X receptors [ligand-gated ion channel receptor] | ||||
 1. | P2X1 | ATP | NA | NA |
 2. | P2X2 | ATP | NA | NA |
 3. | P2X3 | ATP | NA | NA |
 4. | P2X4 | ATP | NA | NA |
 5. | P2X5 | ATP | Cell differentiation | [35] |
 6. | P2X6 | ATP | NA | NA |
 7. | P2X7 | ATP | Cell differentiation | [35] |
2. P2Y receptors [G-protein-coupled receptor] | ||||
 1. | P2Y1 | ADP | Tumour cell proliferation | [35] |
 2. | P2Y2 | ATP = UTP | Tumour cell proliferation | [35] |
 3. | P2Y4 | UTP | NA | NA |
 4. | P2Y6 | UDP | NA | NA |
 5. | P2Y11 | ATP | NA | NA |
 6. | P2Y12 | ADP | EMT during cancer progression | [36] |
 7. | P2Y13 | ADP | NA | NA |
 8. | P2Y14 | UDP - glucose | NA | NA |